Psy-World

Close this window Long term treatment with SSRI and SNRI Please note: Clicking on the link on the reference numbers, for example [1] will open a window with the full reference. Please remember to close the Reference window.  SSRI Fluvoxamine (1) Fluvoxamine vs placebo Randomised double-blind maintenance treatment 1 year Fewer recurrences on fluvoxamine than on placebo Paroxetine (2) Paroxetine vs nortriptyline Open follow-up 18 months in elderly Equal efficacy for the two drugs on preventing recurrence SNRI Milnacipran (3) Milnacipran vs placebo Randomised double-blind maintenance treatment 1 year Fewer recurrences on milnacipran than on placebo Venlafaxine (4) Venlafaxine vs placebo Pooled analysis of 4 clinical trials 6 month and 1 year Fewer recurrences on venlafaxine than placebo Close this window 1. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 55-62. 2. Bump GM, Mulsant BH, Pollock BG, Mazumdar S, Begley AE, Dew MA, Reynolds CF 3rd. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 2001; 13: 38-44. 3. Rouillon F, Warner B, Pezous N, Bisserbe JC, and the Milnacipran recurrence prevention study group. Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Int Clin Psychopharmacol 2000; 15: 133-140. 4. Entsuah AR, Rudolph RL, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996; 11: 137-45.